Thomas Braxton King
CIK 1279309 · Executive Chairman · last filed 2025-09-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALXA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 100
BOTHELL, WA 98021
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACHV | Executive Chairman | 315,142 | $6.74 | $2.12M | -$387.4K | 6 | 2025-09-08 |
| TFF Pharmaceuticals, Inc. (TFFP) Delisted | Director | 1,583 | $0.07 | $103 | $0 | 3 | 2024-07-08 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | — | $1.10 | — | $0 | 4 | 2023-06-08 |
| VIVUS INC (VVUS) Delisted | Interim Chief Executive Office | — | — | — | $0 | 5 | 2020-02-24 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | President & CEO | 77,223 | — | — | -$190.5K | 46 | 2015-11-03 |
Recent Filings · Page 6 of 7
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-08-11 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −12,500 | -$70.9K | EDGAR |
| 2008-07-11 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-05-13 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −12,500 | -$76.5K | EDGAR |
| 2008-05-01 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2008-02-12 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −12,500 | -$83.3K | EDGAR |
| 2008-01-08 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-12-26 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Gift (G) | −2,500 | $0 | EDGAR |
| 2007-11-13 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Sell (S) | −12,500 | -$90.0K | EDGAR |
| 2007-11-07 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | — | — | $0 | EDGAR |
| 2007-08-23 | Alexza Pharmaceuticals Inc. (ALXA) Delisted | Gift (G) | −435 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.